Funding
Funding not disclosed
Founders
Product
Problem
Traditional skin cancer biopsies are invasive, painful, and can result in scarring, leading to patient anxiety and reluctance to undergo necessary diagnostic procedures. The need for specialized medical personnel and laboratory analysis further increases the cost and time associated with skin cancer detection.
Solution
The startup offers a non-invasive microneedle patch technology for extracting skin cells, enabling rapid and painless pre-screening for skin cancer. The patch gently adheres to the skin and painlessly collects cellular material from the epidermis and superficial dermis. This extracted sample can then be analyzed using advanced molecular techniques to identify biomarkers associated with various types of skin cancer. By eliminating the need for surgical biopsies, the technology aims to improve patient comfort, reduce healthcare costs, and accelerate the diagnostic process, leading to earlier detection and treatment of skin cancer.
Target Audience
The primary target audience includes dermatologists, primary care physicians, and individuals at high risk for skin cancer who seek a less invasive and more convenient screening method.
Features
- Microneedle array designed for painless and atraumatic skin cell extraction
- Proprietary patch adhesive for secure and comfortable skin contact
- Integrated cell lysis and stabilization reagents for sample preservation
- Compatibility with downstream molecular analysis techniques, including PCR and next-generation sequencing
- Cloud-based platform for data analysis and reporting
- Telemedicine integration for remote monitoring and diagnosis